PROFESSIONAL EDITION

The largest community of pharma leaders

Bristol Myers Squibb Receives Positive CHMP Opinion for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis

PRINCETON, N.J.–(BUSINESS WIRE)—- $BMY #BMS–BMS Receives Positive CHMP Opinion for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis.

Source Business Wire Health: Pharmaceutical NewsRead More

Recent Articles